Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Tiotropium bromide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
e NEVER place a capsule directly into the Braltus mouthpiece. If you have any problems using Do not use Braltus: the Zonda inhaler, ask your doctor, pharmacist
Printed by Andy Lau, 14 Oct 2025 13:51:07 (UTC +01:00)
page 1 of 3 pages
250208_s2 P Tiotropium (BRALTUS) UK Inha Caps 10mcg 30 CHEM_V4.pdf, Cycle:4, Status:Null
Braltus Braltus contains the active substance tiotropium. Always use this medicine exactly as your doctor Tiotropium helps people who have chronic obstructive pulmonary disease (COPD) to breathe has told you. Check with your doctor or more easily. COPD is a chronic lung disease that pharmacist if you are not sure. causes shortness of breath and coughing. The The recommended dose is to inhale the term COPD is associated with the conditions contents of one capsule once daily with the chronic bronchitis and emphysema. As COPD is Zonda inhaler. One capsule provides the a chronic disease you should use this medicine required daily dose of tiotropium (a delivered every day and not only when you have breathing dose of 10 micrograms of tiotropium); do not problems or other symptoms of COPD. use more than the recommended dose. Braltus is a long-acting bronchodilator that You should try to use this medicine at the same helps to open your airways and makes it easier time every day. This is important because this to get air in and out of the lungs. Regular use medicine is effective over 24 hours. of this medicine can also help you when you The capsules are only for inhalation and not have on-going shortness of breath related to for oral intake. your disease and will help you to minimise the Do not swallow the capsules. effects of the disease on your everyday life. It also helps you to be active longer. Daily use of The Zonda inhaler, which you should put the this medicine will also help to prevent sudden, Braltus capsule into, makes holes in the short-term worsening of your COPD symptoms capsule and allows you to breathe in the powder. The capsules must only be inhaled which may last for several days. The effect of using the Zonda inhaler. Do not use any other this medicine lasts for 24 hours, so you only inhalers to administer Braltus capsules. need to use it once a day. Make sure you know how to use the Zonda This medicine should not be used as a rescue inhaler properly. The instructions for use of the therapy for the treatment of unexpected Zonda inhaler are provided on the other side tightness of the chest, coughing or sudden of this leaflet. Remember to carefully follow attacks of breathlessness or wheezing. Please use a fast-acting 'reliever' (rescue) inhaler, such these instructions for use. Pictures for the correct insertion of the capsule into the as salbutamol instead. Please keep this inhaler are also provided on the inside of the 'reliever' inhaler with you at all times. lid of the carton. To avoid the risk of choking
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Braltus Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and the bottle label after EXP. The expiry date refers to the last day of that month.
Do not refrigerate or freeze. Keep the bottle tightly closed. Store in the original packaging to protect from moisture. Use the product within 30 days (15 capsule bottle) or 60 days (30 capsule bottle) of opening the bottle. The Zonda inhaler should only be used with the bottle of capsules that will either be provided in the same pack as the inhaler, or in the pack bundled separately with the inhaler pack. Do not reuse the inhaler for another bottle of capsules. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. The inhaler device should be disposed of in accordance with local requirements.
What Braltus contains
Zonda Instructions for Use Dear Patient, The Zonda inhaler enables you to inhale the medicine contained in the Braltus capsule that your doctor has prescribed for your breathing problems. Remember to carefully follow your doctor's instructions for using Braltus. The Zonda inhaler is especially designed for Braltus capsules: you must not use it to take any other medication. The capsules must only be inhaled using the Zonda inhaler. Do not use any other inhalers to administer Braltus capsules. Each capsule contains only a small amount of powder. Do not open the capsule or it may not work. The Zonda inhaler should only be used with the bottle of capsules that will either be provided in the same pack, or in the pack bundled separately with the inhaler pack. Do not reuse the inhaler for another bottle of capsules. Discard the Zonda device once the provided capsules use is completed.
Zonda
1. Dust cap 3. Base
5 3
5. Close the mouthpiece until you hear a click, leaving the dust cap open.
2. Mouthpiece
2 1
5
4
4. Piercing button 5. Centre chamber
1
1. Pull the dust cap upwards.
6
2
2. Hold the base of the inhaler firmly and open the mouthpiece by pulling it upwards, in the direction of the arrow.
6. Hold the inhaler with the mouthpiece upwards, and firmly press the piercing button completely in once. Release the button. This will pierce the capsule and allows the medication to be released when you breathe in.
7
7. Breathe out fully. It is important to do this away from the mouthpiece. Avoid breathing into the mouthpiece at any time.
3. Remove a Braltus capsule from the bottle immediately before use and close the bottle tightly. Place one capsule in the centre chamber in the base of the inhaler. Do not store the capsule in the Zonda inhaler.
3
8. Place the mouthpiece in your mouth and keep your head in an upright position. Close your lips around the mouthpiece and breathe in slowly and deeply enough to hear or feel the capsule vibrating inside the centre chamber. Hold your breath for as long as you comfortably can whilst taking the inhaler out of your mouth. Then breathe normally. Repeat steps 7 and 8 to empty the capsule completely.
8
9
4. To avoid the risk of choking NEVER place a capsule directly into the mouthpiece.
9. After use, open the mouthpiece again, and tip out the empty capsule. Close the mouthpiece and dust cap, and store your Zonda inhaler.
The Zonda inhaler is a Medical Device (CE) Manufacturer: Laboratorios LICONSA S.A. Avda. Miralcampo, No 7, Polígono Industrial Miralcampo 19200 Azuqueca de Henares, Guadalajara Spain
4
0051
Printed by Andy Lau, 14 Oct 2025 13:51:07 (UTC +01:00)
250208_s2
page 2 of 3 pages
Braltus (tiotropium) 10mcg Inhalation Powder comes as inhaler containing 10mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Braltus (tiotropium) 10mcg Inhalation Powder is tiotropium bromide.
This leaflet reproduces the patient information leaflet approved for Braltus (tiotropium) 10mcg Inhalation Powder, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Braltus is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).
Braltus is indicated for use in adults.
Posology
Route of administration: Inhalation use.
Recommended Dose
Adults 18 years of age and older:
Inhalation of the contents of one capsule once daily with the Zonda inhaler.
Inhalation should be at the same time of day each day.
The recommended dose should not be exceeded.
The delivered dose of a single capsule (10 micrograms) is sufficient and is the standard dose for treatment with Braltus..
Braltus capsules are for inhalation only; they must not be swallowed.
Braltus capsules must only be inhaled with the Zonda inhaler.
Special populations
Elderly patients can use tiotropium bromide at the recommended dose.
Patients with mild renal impairment (creatinine clearance >50 ml/min) can use tiotropium bromide at the recommended dose. For patients with moderate to severe impairment (creatinine clearance ≤50 ml/min) see section 4.4 and section 5.2.
Hepatically impaired patients can use tiotropium bromide at the recommended dose (see section 5.2).
Paediatric population
Braltus should not be used in children or adolescents under 18 years of age. Safety and efficacy have not been established. No data are available.
There is no relevant use for tiotropium bromide in the paediatric population for the indication of COPD.
The safety and efficacy of tiotropium bromide in cystic fibrosis in children and adolescents aged less than 18 years have not been established. No data are available.
Method of administration/Instructions for Use and Handling
To ensure proper administration of the medicinal product, the patient should be trained in the use of the inhaler by either the prescribing physician or by other healthcare professionals.
The Zonda inhaler is especially designed for Braltus capsules; patients must not use it to take any other medication. Braltus capsules must only be inhaled using the Zonda inhaler. Patients must not use any other inhalers to take Braltus capsules. Advise the patient to carefully follow the instructions for use in the patient leaflet. Make the patient aware of the additional pictures on the inside of the lid of the carton which illustrate the correct method for insertion of the capsule into the inhaler. To avoid the risk of choking, instruct the patient to NEVER place a capsule directly into the mouthpiece.
The Zonda inhaler should only be used with the bottle of capsules that will either be provided in the same pack as the inhaler, or in the pack bundled separately with the inhaler pack. Discard the Zonda device once the provided capsules use is completed.
1. Dust cap
2. Mouthpiece
3. Base
4. Piercing button
5. Centre chamber
1. Pull the dust cap upwards.
2. Hold the base of the inhaler firmly and open the mouthpiece by pulling it upwards, in the direction of the arrow to open it.
3. Remove a Braltus capsule from the bottle immediately before use and close the bottle tightly. Place one capsule in the centre chamber in the base of the inhaler. Do not store the capsule in the Zonda inhaler.
4. To avoid the risk of choking, NEVER place a capsule directly into the mouthpiece.
5. Close the mouthpiece until a click is heard, leaving the dust cap open.
6. Hold the inhaler with the mouthpiece upwards, and press the piercing button completely in once. Release the button. This will pierce the capsule and allows the medication to be released when the patient breathes in.
7. Breathe out fully. It is important to do this away from the mouthpiece. Avoid breathing into the mouthpiece at any time.
8. Place the mouthpiece in your mouth and keep your head in an upright position. Close your lips around the mouthpiece and breathe in slowly and deeply enough to hear or feel the capsule vibrating inside the centre chamber.
Hold your breath for as long as you comfortably can whilst taking the inhaler out of your mouth. Then breathe normally. Repeat steps 7 and 8 to empty the capsule completely.
9. After use, open the mouthpiece again, and tip out the empty capsule. Close the mouthpiece and dust cap, and store the Zonda inhaler.
Braltus capsules contain only a small amount of powder, so that the capsule is only partially filled.
If necessary, the patient may wipe the mouthpiece of the Zonda inhaler after use with a dry cloth or tissue.
Hypersensitivity to the active substance tiotropium bromide, atropine or its derivatives, e.g. ipratropium or oxitropium, or to any of the excipients listed in section 6.1, including lactose monohydrate which contains milk protein.
Tiotropium bromide, as a once daily maintenance bronchodilator, should not be used for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy.
Immediate hypersensitivity reactions may occur after administration of tiotropium bromide inhalation powder.
Consistent with its anticholinergic activity, tiotropium bromide should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction. (see section 4.8).
As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting bronchodilator and should be treated straightaway. Braltus should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
Tiotropium should be used with caution in patients with recent myocardial infarction <6 months; any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy in the past year; hospitalisation for heart failure (NYHA Class III or IV) within the past year. These patients were excluded from the clinical trials and these conditions may be affected by the anticholinergic mechanism of action.
As plasma concentration increases with decreased renal function in patients with moderate to severe renal impairment (creatinine clearance ≤50 ml/min), tiotropium bromide should be used only if the expected benefit outweighs the potential risk.There is no long term experience in patients with severe renal impairment (see section 5.2).
Patients should be cautioned to avoid getting the drug powder into their eyes. They should be advised that this may result in precipitation or worsening of narrow-angle glaucoma, eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema. Should any combination of these eye symptoms develop, patients should stop using tiotropium bromide and consult a specialist immediately.
Dry mouth, which has been observed with anti-cholinergic treatment, may in the long term be associated with dental caries.
Tiotropium bromide should not be used more frequently than once daily (see section 4.9).
Each capsule contains 18 mg lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. The excipient lactose may contain trace amounts of milk proteins which may cause reactions in those with severe hypersensitivity or allergy to milk protein.
Although no formal drug interaction studies have been performed, tiotropium bromide inhalation powder has been used concomitantly with other drugs without clinical evidence of drug interactions. These include sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids, commonly used in the treatment of COPD.
Use of long-acting β2 agonists (LABA) or inhaled corticosteroids (ICS) was not found to alter the exposure to tiotropium.
The co-administration of tiotropium bromide with other anticholinergic drugs has not been studied and is therefore not recommended.
Fertility
Clinical data on fertility are not available for tiotropium. A non-clinical study performed with tiotropium showed no indication of any adverse effect on fertility (see section 5.3).
Pregnancy
There is a very limited amount of data from the use of tiotropium in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant doses (see 5.3). As a precautionary measure, it is preferable to avoid the use of Braltus during pregnancy.
Breast-feeding
It is unknown whether tiotropium bromide is excreted in human breast milk. Despite studies in rodents which have demonstrated that excretion of tiotropium bromide in breast milk occurs only in small amounts, use of tiotropium bromide is not recommended during breast-feeding. Tiotropium bromide is a long-acting compound. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Braltus should be made taking into account the benefit of breast-feeding to the child and the benefit of Braltus therapy to the woman.
No studies on the effects on the ability to drive and use machines have been performed. The occurrence of dizziness, blurred vision, or headache may influence the ability to drive and use machinery.
Many of the listed undesirable effects can be assigned to the anticholinergic properties of tiotropium bromide.
The frequencies assigned to the undesirable effects listed below are based on crude incidence rates of adverse drug reactions (i.e. events attributed to tiotropium) observed in the tiotropium group (9,647 patients) from 28 pooled placebo-controlled clinical trials with treatment periods ranging from four weeks to four years.
Frequency is defined using the following convention:
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
System Organ Class/MedDRA Preferred Term
Frequency
Metabolism and nutrition disorders
Dehydration
Not known
Nervous system disorders
Dizziness
Headache
Taste disorders
Insomnia
Uncommon
Uncommon
Uncommon
Rare
Eye disorders
Vision blurred
Glaucoma
Intraocular pressure increased
Uncommon
Rare
Rare
Cardiac disorders
Atrial fibrillation
Supraventricular tachycardia
Tachycardia
Palpitations
Uncommon
Rare
Rare
Rare
Respiratory, thoracic and mediastinal disorders
Pharyngitis
Dysphonia
Cough
Bronchospasm
Epistaxis
Laryngitis
Sinusitis
Uncommon
Uncommon
Uncommon
Rare
Rare
Rare
Rare
Gastrointestinal disorders
Dry mouth
Gastro-oesophageal reflux disease
Constipation
Oropharyngeal candidiasis
Intestinal obstruction, including ileus paralytic
Gingivitis
Glossitis
Dysphagia
Stomatitis
Nausea
Dental caries
Common
Uncommon
Uncommon
Uncommon
Rare
Rare
Rare
Rare
Rare
Rare
Not known
Skin and subcutaneous tissue disorders, immune system disorders
Rash
Urticaria
Pruritus
Hypersensitivity (including immediate reactions)
Angioedema
Anaphylactic reaction
Skin infection, skin ulcer
Dry skin
Uncommon
Rare
Rare
Rare
Rare
Not known
Not known
Not known
Musculoskeletal and connective tissue disorders
Joint swelling
Not known
Renal and urinary disorders
Dysuria
Urinary retention
Urinary tract infection
Uncommon
Uncommon
Rare
Allergic reactions
The excipient lactose may contain trace amounts of milk proteins which may cause reactions in those with severe hypersensitivity or allergy to milk protein.
Tiotropium bromide should be discontinued immediately if a hypersensitivity or allergic reaction occurs and the patient should then be managed in the usual way.
Paradoxical bronchospasm
As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting bronchodilator and should be treated straightaway. Braltus should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
Description of selected adverse reactions
In controlled clinical studies, the commonly observed undesirable effects were anticholinergic undesirable effects such as dry mouth which occurred in approximately 4% of patients.
In 28 clinical trials, dry mouth led to discontinuation in 18 of 9,647 tiotropium treated patients (0.2%).
Serious undesirable effects consistent with anticholinergic effects include glaucoma, constipation and intestinal obstruction including ileus paralytic as well as urinary retention.
Other special population
An increase in anticholinergic effects may occur with increasing age.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
High doses of tiotropium bromide may lead to anticholinergic signs and symptoms.
However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 340 microgram tiotropium bromide in healthy volunteers.
Additionally, no relevant adverse effects, beyond dry mouth, were observed following 7 day dosing of up to 170 microgram tiotropium bromide in healthy volunteers. In a multiple dose study in COPD patients with a maximum daily dose of 43 microgram tiotropium bromide over four weeks no significant undesirable effects have been observed.
Acute intoxication by inadvertent oral ingestion of tiotropium bromide capsules is unlikely due to low oral bioavailability.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Braltus (tiotropium) 10mcg Inhalation Powder. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.